Northwestern Mutual Wealth Management Co. Cuts Stake in Eli Lilly and Company $LLY

Northwestern Mutual Wealth Management Co. reduced its position in Eli Lilly and Company (NYSE:LLY) by 99.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,829 shares of the company’s stock after selling 231,467 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Eli Lilly and Company were worth $1,966,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Brighton Jones LLC grew its holdings in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. Schnieders Capital Management LLC. grew its holdings in Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after purchasing an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC purchased a new position in Eli Lilly and Company in the second quarter worth $356,000. Finally, Nebula Research & Development LLC purchased a new position in Eli Lilly and Company in the second quarter worth $749,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 0.2%

LLY stock opened at $1,066.77 on Wednesday. The firm has a 50 day moving average of $946.28 and a 200 day moving average of $1,006.64. The stock has a market capitalization of $1.00 trillion, a PE ratio of 37.90, a price-to-earnings-growth ratio of 1.16 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period last year, the business earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on LLY shares. Leerink Partners set a $1,119.00 target price on shares of Eli Lilly and Company in a research note on Tuesday. Argus lifted their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Scotiabank reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Daiwa Securities Group lifted their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced it will acquire three vaccine developers — Curevo, LimmaTech Biologics, and Vaccine Company — in deals worth up to about $3.8 billion, expanding its infectious-disease and vaccine portfolio beyond diabetes and obesity. Lilly announces three acquisitions to build infectious disease portfolio
• Positive Sentiment: Investors also reacted to strong news from Lilly’s experimental gene therapy VERVE-102, which cut LDL cholesterol and PCSK9 sharply in early trial data, reinforcing optimism around the company’s broader growth pipeline. VERVE-102 trial results
• Positive Sentiment: Analysts and media coverage continued to highlight Lilly as a long-term winner in obesity and pharma, supported by persistent demand for its weight-loss drugs and upbeat commentary on its growth prospects. Motley Fool article on undervaluation
• Neutral Sentiment: Broader market gains and hopes for a diplomatic resolution between the U.S. and Iran helped lift equities overall, providing a supportive backdrop for Lilly alongside the company-specific headlines. Market wrap article
• Neutral Sentiment: Some healthcare-sector weakness on the day may have partially offset the company-specific optimism, but it does not appear to be the main driver for LLY. Healthcare sector decline article

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.